Combined Action of Anti-MUC1 Monoclonal Antibody and Pyrazole-Platinum(II) Complexes Reveals Higher Effectiveness towards Apoptotic Response in Comparison with Monotherapy in AGS Gastric Cancer Cells

Mechanism of the GALNT family proteins in regulating tumorigenesis and development of lung cancer (Review)

Lung cancer is one of the most common and lethal malignant tumors. Currently, surgical resection is the most effective treatment for early-stage lung cancer, and often results in favorable recovery outcomes. Therefore, early detection and control of lung cancer occurrence, invasion and metastasis are crucial for improving patient survival rates. Identifying tumor markers for lung cancer plays a vital role in facilitating early detection and control of its progression. The GALNT family proteins are enzymes that regulate the initial step in mucin O-glycan synthesis. It has been revealed that the expression of polypeptide N-acetyl-galactosamine-transferase (GALNT) family members is dysregulated in various tumors, and is closely associated with tumorigenesis, tumor cell growth, metastasis, adhesion, and serves as an important early indicator of tumor development. The present review compiles and analyzes findings concerning the role of GALNT family proteins in regulating lung cancer, with the goals of elucidating their mechanisms in lung cancer occurrence and progression and providing insights for improving the prognosis and therapeutic treatment of patients with lung cancer.

Anti-cancer effects of pyrazole-platinum(II) complexes combined with anti-MUC1 monoclonal antibody versus monotherapy in DLD-1 and HT-29 colon cancer cells

The membrane-bound MUC1 mucin is overexpressed and aberrantly glycosylated in many epithelium origin cancers. One of the promising strategies in cancer therapy is combining monoclonal antibodies against cancer related antigens, like MUC1, with chemotherapeutics. In the study we evaluated the potency of cisplatin (cisPt), two pyrazole-platinum(II) complexes PtPz4, PtPz6, and anti-MUC1 mAb applied as monotherapy, as well as the chemotherapeutics administrated with antibody, towards apoptotic response and cancer-related carbohydrate antigens (TACAs) in DLD-1 and HT-29 colon cancer cells. To assess the impact of the tested compounds on the examined factors flow cytometry, RT-PCR, Western blotting and ELISA were utilized. The combined therapy was more potent than monotherapy towards Bcl-2, Bid, caspases and TACAs of both cell lines. Combined therapy applied in DLD-1 cells induced apoptosis, was more effective than monotherapy in relation to p53, Bcl-xL, Bax, and Bim. In HT-29 cells, anti-MUC1 administrated with the drugs was more potent than monotherapy towards Bad. The proposed anti-MUC1/cisPt and pyrazole-platinum(II) complexes PtPz4, PtPz6 combined therapy may be promising anti-colon cancer therapy.